CAPR · Capricor Therapeutics Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 6.59 USD |
|---|---|
| 1-day change | -4.2% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 9 / 3 / 42 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 21 / 25 / 1 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -14.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +81.3% |
| Market cap (USD) | $2.0B |